Interestingly, the dysregulation of PROX1, along with PDPN, VEGFR3, and EDΝRA, seems to play a pathogenetic role in the development of post-radiotherapy breast angiosarcomas, which, through the identification of those specific genes, present a discriminating genetic “signature” [53]. The gene discussed is FLT4; the disease is breast angiosarcoma.